颅内静脉窦血栓形成抗凝治疗的研究进展  

Advances in anticoagulation of cerebral venous sinus thrombosis

作　　者：陈雪 王浩玥 李鸣明[2] 葛朝明[2] CHEN Xue;WANG Haoyue;LI Mingming(the Second Clinical Medical College,Lanzhou University,Lanzhou 730000,China)

机构地区：[1]兰州大学第二临床医学院,730000 [2]兰州大学第二医院神经内科

出　　处：《临床神经病学杂志》2025年第2期139-142,共4页Journal of Clinical Neurology

基　　金：兰州市科技计划项目(2023-4-20)。

摘　　要：颅内静脉窦血栓(CVST)是一种罕见的静脉系统疾病,是引起脑静脉卒中的主要病因。全身抗凝治疗是CVST治疗的关键,急性期传统治疗选择肝素桥接维生素K拮抗剂。随着维生素K拮抗剂的广泛应用,暴露出治疗窗窄、食物与药物的相互作用、需频繁监测国际化标准化比值等缺点,而直接口服抗凝剂在同等疗效下却无上述问题,因此直接口服抗凝剂能否替代维生素K拮抗剂成为研究热点。本文主要围绕直接口服抗凝剂在CVST的研究进展及维生素K拮抗剂与直接口服抗凝剂对CVST抗凝治疗在有效性及安全性方面的研究进展进行综述。Cerebral venous sinus thrombosis(CVST)is a rare disease of the venous system and a major cause of cerebral venous stroke.Systemic anticoagulation remains the key to the treatment of CVST,with heparin-bridged vitamin K antagonists being the traditional treatment of choice in the acute phase with the wide application of vitamin K antagonists,the disadvantages of narrow therapeutic window,food-drug interactions,and the need for frequent monitoring of the internationalized normative ratio(INR)have been exposed,whereas direct oral anticoagulants do not have the above mentioned problems under the same efficacy,so whether direct oral anticoagulants can replace vitamin K antagonists has become a major research hotspot.This article mainly focuses on the research progress of direct oral anticoagulants in CVST and the research progress of vitamin K antagonists and direct oral anticoagulants in CVST anticoagulation therapy in terms of effectiveness and safety.

关 键 词：颅内静脉窦血栓 维生素K拮抗剂 直接口服抗凝剂 

分 类 号：R743.3[医药卫生—神经病学与精神病学]